October 14, 2024 11:34 AM EDTUpdated 04:13 PM

Pfizer details results from failed Phase 3 trial of Duchenne muscular dystrophy gene therapy

Lei Lei Wu

News Reporter

The full results from Pfizer’s pivotal study of its Duchenne muscular dystrophy gene therapy show patients saw no significant functional benefit one year after receiving …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Pfizer details results from failed Phase 3 trial of Duchenne muscular dystrophy gene therapy

Lei Lei Wu

News Reporter

Sign up to read this article for free.

Novartis ends mid-stage IPF trial, will keep testing drug in PAH

Updated: Lundbeck makes $2.6B cash move for Longboard a month after starting Phase 3 in Dravet syndrome

Jasper shares rally as chronic hives drug scores in small, early trial

Two GSK trials with long-acting drug in chronic rhinosinusitis hit primary endpoints

Exclusive: British startup raises $16M to find genes that rewind the epigenetic clock

Join the GenScript Biotech Global Forum: Unlocking Innovations in Cell and Gene Therapies

Pfiz­er de­tails re­sults from failed Phase 3 tri­al of Duchenne mus­cu­lar dy­s­tro­phy gene ther­a­py

Lei Lei Wu

News Reporter

Sign up to read this article for free.

No­var­tis ends mid-stage IPF tri­al, will keep test­ing drug in PAH

Up­dat­ed: Lund­beck makes $2.6B cash move for Long­board a month af­ter start­ing Phase 3 in Dravet syn­drome

Jasper shares ral­ly as chron­ic hives drug scores in small, ear­ly tri­al

Two GSK tri­als with long-act­ing drug in chron­ic rhi­nos­i­nusi­tis hit pri­ma­ry end­points

Ex­clu­sive: British start­up rais­es $16M to find genes that rewind the epi­ge­net­ic clock

Join the Gen­Script Biotech Glob­al Fo­rum: Un­lock­ing In­no­va­tions in Cell and Gene Ther­a­pies

Pfizer details results from failed Phase 3 trial of Duchenne muscular dystrophy gene therapy

Novartis ends mid-stage IPF trial, will keep testing drug in PAH

Updated: Lundbeck makes $2.6B cash move for Longboard a month after starting Phase 3 in Dravet syndrome

Jasper shares rally as chronic hives drug scores in small, early trial

Two GSK trials with long-acting drug in chronic rhinosinusitis hit primary endpoints

Exclusive: British startup raises $16M to find genes that rewind the epigenetic clock

Join the GenScript Biotech Global Forum: Unlocking Innovations in Cell and Gene Therapies